Showing results (241-250 of 258) with videos related to
Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid TumorsAnish Thomas, Christophe E Redon, Linda Sciuto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2021
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research GroupRoisin M Connolly, Fengmin Zhao, Kathy D Miller, et al.Molecular Cancer Therapeutics|June 24, 2018
Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal AdenocarcinomaPaul L Feingold, Deborah R Surman, Kate Brown, et al.Nature Chemical Biology|September 28, 2011
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90Kamalika Moulick, James H Ahn, Hongliang Zong, et al.BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.Cell Stress & Chaperones|January 5, 2023
Second Virtual International Symposium on Cellular and Organismal Stress Responses, September 8-9, 2022Patricija van Oosten-Hawle, Sarah J Backe, Anat Ben-Zvi, et al.BJU International|September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.JAMA Oncology|September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled TrialDickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary CancerHeather J Chalfin, Tiziano Pramparo, Amir Mortazavi, et al.Pageof 26